Accumulation of RNA CUG repeats in myotonic dystrophy type 1 (DM1) patients leads to the induction of a CUG-binding protein, CUGBP1, which increases translation of several proteins that are required for myogenesis. In this paper, we examine the role of overexpression of CUGBP1 in DM1 muscle pathology using transgenic mice that overexpress CUGBP1 in skeletal muscle. Our data demonstrate that the elevation of CUGBP1 in skeletal muscle causes overexpression of MEF2A and p21 to levels that are significantly higher than those in skeletal muscle of wild type animals. A similar induction of these proteins is observed in skeletal muscle of DM1 patients with increased levels of CUGBP1. Immunohistological analysis showed that the skeletal muscle from mice overexpressing CUGBP1 is characterized by a developmental delay, muscular dystrophy, and myofiber-type switch: increase of slow/oxidative fibers and the reduction of fast fibers. Examination of molecular mechanisms by which CUGBP1 up-regulates MEF2A shows that CUGBP1 increases translation of MEF2A via direct interaction with GCN repeats located within MEF2A mRNA. Our data suggest that CUGBP1-mediated overexpression of MEF2A and p21 inhibits myogenesis and contributes to the development of muscle deficiency in DM1 patients.
DM1
1 is a multisystem disease mainly characterized by defects in skeletal muscle with the involvement of many tissues and systems such as cardiac muscle, brain, eye, and endocrine system (1). DM1 is caused by an expansion of CTG trinucleotide repeats within the 3Ј-untranslated region of the myotonin protein kinase gene (2) . In DM1 patients, the size of DNA CTG expansion correlates with the severity of the disease. Patients with CTG expansion containing 50 -80 CTG repeats are almost asymptomatic. Individuals bearing the myotonin protein kinase gene with 100 -500 CTG repeats develop a disease in adult life (classical adult form of DM1) that is characterized by a progressive muscle wasting with myotonia. The most severe form of DM1, congenital disease, affects patients before or after birth and is associated with long CTG expansions (up to 2,000 repeats). This form of disease is characterized by a delay or arrest of skeletal muscle development (3) . Although there is an overlap in range of repeats between different forms of DM1, there is a clear correlation of repeat number with severity of phenotype and reduction of age of onset.
Investigations of molecular alterations in DM1 suggest that the expansion of CTG repeats causes the DM1 pathology through different mechanisms, mediated at both DNA and RNA levels. It has been shown that CTG repeats reduce expression of myotonin protein kinase in cis (4), causing abnormalities in cardiac muscle (5) . CTG repeats also affect transcription of genes adjacent to myotonin protein kinase (6) , leading to the development of cataracts (7, 8) . A number of recent studies indicate that other symptoms in DM1 such as myotonia (9, 10) , delay of skeletal muscle differentiation (11, 12) , and a resistance to insulin (13) are mediated through an RNA-based mechanism. According to this mechanism, RNA CUG repeats cause the DM1 disease via specific RNA CUGbinding proteins (14) .
Two families of RNA CUG-binding proteins have been identified: CUGBP (RNA-binding protein, binding to RNA CUG repeats) (15) (16) (17) and EXP (also known as MNBL, muscle blind) proteins (18) . One of the members of the CUGBP family, CUGBP1, contributes to at least three symptoms of DM1: the delay of skeletal muscle differentiation (12) , myotonia (19) , and the insulin resistance (13) . Previous studies showed that the expansion of CUG repeats in DM1 leads to a 3-5-fold elevation of CUGBP1 binding activity and protein levels (13, 19 -21) , perhaps by stabilizing CUGBP1 protein within RNA CUG-CUGBP1 complexes (21) . CUGBP1 possesses two major biological functions: regulation of splicing and translation (12, 20 -22) . Translational function of CUGBP1 was investigated mainly in cultured cells. These studies showed that CUGBP1 increases translation of p21 (12) and translation of a dominant negative isoform of transcription factor CCAAT/enhancer-binding protein ␤, LIP (22) . It has been shown that, in tissue culture models, CUGBP1-mediated induction of p21 is required for proper differentiation of myocytes (12) . However, the role of translational function of CUGBP1 in vivo has not been addressed.
To examine the role of translational activity of CUGBP1 in development of skeletal muscle deficiency in DM1 patients, we generated transgenic mice that overexpress CUGBP1 mainly in skeletal muscle and to a lesser extent in the heart. We found that elevation of CUGBP1 causes overexpression of its translational targets p21 and MEF2A (transcription factor, myocyte enhancer factor 2A) in skeletal muscle. These alterations cause a muscular dystrophy, an increase of slow fibers, and delay of muscle development.
EXPERIMENTAL PROCEDURES
UV Cross-linking-RNA transcripts encoding 123 CUG repeats, the full-length wild type, and mutant MEF2A mRNAs lacking the CUGBP1 binding site were synthesized in an in vitro transcription assay (Roche Applied Science) and incubated with 10 -20 g of purified proteins as described (12) . After UV cross-linking, the samples were treated with RNase A (2 units/10 l) and separated by PAGE with 0.1% SDS. Where indicated, MEF2A riboprobe containing the (GCA) 9 repeat (CUGBP1 binding site within MEF2A mRNA) or sORF riboprobe specific for C/EBP␤ was used.
Generation of CUGBP1 Transgenic Mice-The experiments related to transgenic mice complied with federal guidelines and institutional policies. The full-length human CUGBP1 cDNA was amplified from a parental plasmid (17) with CUGBP1-specific primers. The sequence of the forward primer is as follows: 5Ј-TCA AAG AAA ATG AAC GGC ACC CTG-3Ј. The sequence of the reverse primer fused in frame with a short sequence coding for 6 histidines is as follows: 5Ј-ATG GTG ATG GTG ATG ATG GTA GGG CTT GCT GTC ATT CTT CGA-3Ј. The CUGBP1 cDNA fused with the track of histidines on its C terminus was cloned into BS vector containing chicken ␤-actin promoter connected with cytomegalovirus enhancer (a gift from Dr. Schneider, Baylor College of Medicine). Transgenic construct was injected into mouse FVB inbred eggs at DNX Transgenic Sciences Co. (Princeton, NJ).
Genotyping of Transgenic Mice-Progenies were genotyped by PCR with CUGBP1-specific primers. The sequence of forward primer is 5Ј-GCT GCA TTA GAA GCT CAG AAT GCT-3Ј. The reverse primer has a sequence 5Ј-AGG TTT CAT CTG TAT AGG GTG ATG-3Ј. Two PCR products of different size from both wild type (540 bp) and mutant alleles (78 bp) were synthesized simultaneously. The size of PCR product from mutant allele is smaller because the transgene lacks introns.
Tissue Culture-Mouse C2C12 myoblasts and human primary myoblast cultures were grown in 10-cm dishes in myoblast growth medium at 60% of density. Differentiation was induced by a switch of growth medium to fusion medium as described (12) . Differentiating myoblasts were maintained for 5 days with medium changes occurring every day.
Northern Analysis-Total cellular RNA was extracted with TRI Reagent (Molecular Research Center, Inc.) from C2C12 myoblasts and myotubes at different time points of differentiation. RNA was hybridized with CUGBP1 probe as described (15) . Levels of CUGBP1 mRNA (7 ϩ 9 kb) were calculated as a ratio to 18 S rRNA control.
Immunostaining of Mouse Tissues-Paraffin and frozen sections were prepared from vastus or plantaris muscles from wild type and mutant mice with different numbers of CUGBP1 copies of the matching age and gender. Muscle sections were stained with H/E at the Baylor College of Medicine Histology Core. For immunoanalysis, sections were blocked with 1% bovine serum albumin in phosphate-buffered saline for 1 h and incubated for 1 h with antibodies against MEF2 (C-21; 1:1,000), myoglobin (sc-8081; 1:200) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), fast myosin (MY-32; 1:100), and slow myosin heavy chain (NOQ7.54D; 1:50) (Sigma). Rhodamine-labeled anti-rabbit and antimouse immunoglobulins from Santa Cruz Biotechnology were used as secondary antibodies with dilution 1:200. Images were analyzed in Microscopic Core Facilities of Aging Center and Department of Molecular and Cellular Biology at Baylor College of Medicine.
Isolation of Proteins and Western Blotting Analysis-Whole protein extracts from mouse tissues were prepared with radioimmune precipitation buffer. Cytoplasmic, nuclear, and whole cell extracts from cultured cells were isolated as described (12) . The primary antibodies were rabbit anti-CUGBP1, MEF2 (C-21), myoglobin (sc-8081), and MyoD (myogenic transcription factor) (C-20) and mouse p21 (H164), myogenin (CF5D), fast (MY-32) and slow myosin (NOQ7.54D), and ␣-tubulin (TU-02). Detection was performed using the ECL kit (Pierce). Membranes were stripped and reprobed with control antibodies (␣-tubulin or actin), and results were quantified by densitometer analysis.
The Effect of CUGBP1 on MEF2A Levels in Cultured Cells-C2C12 cells were transfected with empty pcDNA vector and with recombinant plasmid containing CUGBP1 in pcDNA vector using FuGene 6 protocol. Protein extracts were isolated in 48 h after transfection and subjected to Western blotting with antibodies against His tag, CUGBP1, and MEF2A. CUGBP1 and MEF2A protein levels were calculated as a ratio to ␤-actin. To visualize the effects of CUGBP1 on MEF2A levels, C2C12 cells grown in slides were transfected with GFP as control and with CUGBP1 cloned into GFP vector. Cells were fixed and subjected to IF with antibodies against MEF2A using secondary antibodies labeled with rhodamine. CUGBP1 (green signal) and MEF2A (red signal) were analyzed at ϫ40 magnification.
Examination of MEF2A Translation in Tissue Culture-One set of plates with C2C12 cells was co-transfected with MEF2A and CUGBP1, and another set was co-transfected with MEF2A and empty vector. One day after transfection, the growth medium was replaced with Met-free medium. In 24 h, Met-deficient medium was complemented with [ 35 S]Met, and whole cell protein extracts were prepared in 0, 1, 2, 4, and 8 h after the addition of [ 35 S]Met. Protein extracts were diluted with phosphate-buffered saline buffer and incubated with antibodies against MEF2A (1:100) for 4 h at 4°C, following incubation with protein Aagarose for 1 h. Immunoprecipitates were collected by centrifugation at 6,000 rpm for 10 min, washed three times with 1 ml of phosphatebuffered saline, resuspended in the loading buffer, and analyzed by polyacrylamide gel electrophoresis.
Inhibition of CUGBP1 by siRNA-Two RNA CUGBP1 primers were synthesized in Qiagen to target the following CUGBP1 sequence: 5Ј-AAT TTG GCT GCA CTA GCT GCT-3Ј. The sequence of the first primer is r(UUUGGCUGCACUAGCUGCU)d(TT). The sequence of the second primer is r(AGCAGCUAGUGCAGCCAAA)d(TT). These primers were annealed to make double-stranded siRNA-CUGBP1. Transfection of siRNA CUGBP1 was performed according to the Qiagen protocol. C2C12 cells were grown at 70% density. Enhancer R was mixed with siRNA oligonucleotide and transfection reagent in a ratio of 2:1:2.5. Protein extracts were prepared from proliferating and differentiating myoblasts transfected with siRNA. In control plates, no siRNA was added.
Translation in an in Vitro Cell-free System-MEF2A plasmid was identified by screening of a human cardiac cDNA library with a GCA triplet repeat probe. GCA deletion mutant was generated by using QuikChange TM site-directed mutagenesis kit (Stratagene). The sequence of forward mutagenic primer is 5Ј-TGG CGG CGG CTG GAA GCC CGA TGG GGT CAT-3Ј. Rabbit reticulocyte lysate was programmed with wild type and mutant MEF2A mRNAs, and increased amounts of purified CUGBP1 were added to the incubation mixture. Translational products were subjected to SDS-PAGE and autoradiography.
Interaction of CUGBP1 and MEF2A mRNA in Vivo-C2C12 myoblasts were grown in the myoblast medium until 80% density and then subjected to differentiation in the fusion medium during 5 days. Cytoplasmic protein extracts were collected from C2C12 differentiating myoblasts in cytoplasmic buffer (20 mM Tris-HCl, pH 7.5, 30 mM KCl, 5 mM EDTA, and 5 mM MgCl 2 ) containing RNase inhibitors. CUGBP1 was immunoprecipitated with monoclonal antibodies 3B1. RNA was extracted by phenol-chloroform and reverse-transcribed with AML using oligo(dT) primer. PCR was performed with primers specific to mouse MEF2A mRNA. The sequence of the forward primer was 5Ј-GATGTT-GAGCACTACAGACCTCA-3Ј, and the sequence of the reverse primer was 5Ј-CTCCCCTGTGGACAGTCTGAGCA-3Ј. The size of the PCR product with MEF2A primers was 743 bp.
Myogenic Conversion of Fibroblasts into Myoblasts-Mouse fibroblasts 10T1/2 were grown onto four-chamber slides in Dulbecco's modified Eagle's medium with 10% fetal bovine serum. Cells grown at 60% of density were transfected with plasmids expressing MyoD, wild type and deletion mutant MEF2A, and the full-length or truncated CUGBP1. The amount of plasmid DNA was 0.2 g per chamber and remained constant in all experiments. When one plasmid was used instead of two or three, the amount of DNA was adjusted with pcDNA vector. Transfection was performed with FuGene. In 2 days after transfection, fibroblast growth medium was replaced with myoblast fusion medium. Cells were grown for 5 days with medium changed every day. Cells were fixed with 4% formaldehyde for 30 min with two changes of fresh formaldehyde. Slides were blocked in 1% bovine serum albumin in phosphate-buffered saline containing goat serum (dilution 1:50) for 2 h. After blocking, slides were incubated with mouse antibodies against fast myosin (Sigma; dilution 1:50) and rabbit antibodies against MyoD (Santa Cruz Biotechnology; 1:50). Secondary anti-rabbit antibodies labeled with rhodamine or anti-mouse antibodies labeled with fluorescein isothiocyanate (Santa Cruz Biotechnology) were used at a dilution of 1:200.
RESULTS

Generation of CUGBP1 Transgenic
Mice-The full-length CUGBP1 coding region was placed under a modified ␤-actin promoter, which is mainly active in skeletal muscle and to a lesser extent in the heart (23), and fused on the C terminus to an oligonucleotide coding for 6 His amino acids. The resulting transgenic construct was injected into inbred eggs of FVB mice, and pups were genotyped by PCR with CUGBP1-specific primers. The expression of transgenic protein (His-CUGBP1) was verified by Western blotting with antibodies to His tag (Fig. 1,  A and B) . We first examined expression of His-CUGBP1 in different tissues of CUGBP1 transgenic mice. In agreement with previous publications (23), ␤-actin promoter fused with cytomegalovirus enhancer directs the expression of His-CUGBP1 primarily in skeletal muscle and to a lesser extent in cardiac muscle (Fig. 1A) . Within the sensitivity of Western blot analysis, we did not detect His-CUGBP1 in brain, spleen, and kidney (Fig. 1A) . We have generated five lines of CUGBP1 transgenic animals ( Table I ). The analysis of His-CUGBP1 in skeletal muscle of these animals showed that the expression of His-CUGBP1 is increased to different levels (Fig. 1B) . In addition, we found that the expression of His-CUGBP1 leads to a 2-3-fold elevation of the endogenous CUGBP1 levels (Fig. 1C) . This estimate was done using protein extracts from vastus muscles of 3-5 mice of each line and 17 wild type mice. The mechanisms by which the transgenic His-CUGBP1 protein induces protein levels of endogenous CUGBP1 are unknown. Our data also showed that CUGBP1 immunoreactive proteins migrate as several bands, perhaps because of different levels in phosphorylation (24) . To examine whether these immunoreactive bands are isoforms of His-CUGBP1, we immunoprecipitated His-CUGBP1 with polyclonal antibodies to His and performed a two-dimensional gel electrophoresis followed by Western blotting with monoclonal antibodies to CUGBP1. Fig.  1D shows that His-CUGBP1 migrates as several spots located between pH 6.0 and 8.0. Acidic isoforms of His-CUGBP1 represent phosphorylated forms of CUGBP1, since a treatment of His-IPs with CIP shifts these isoforms to the alkali region of the strip. Given the elevation of both His-CUGBP1 and endogenous CUGBP1, as well as phosphorylated isoforms of CUGBP1, CUGBP1 levels were calculated as a ratio of all of these isoforms in transgenic animals to endo-CUGBP1 in wild type animals. These calculations showed that an increase of Table I ). C, Western blotting of His-CUGBP1 with antibodies against CUGBP1. Western blotting with protein extracts isolated from skeletal muscle of wild type, CTG transgenic (36) , and CUGBP1 transgenic mice (line 36) was performed with antibodies against CUGBP1. The first lane was loaded with CUGBP1 purified from HeLa cells. The red arrows on the right show positions of hyperphosphorylated forms of CUGBP1. The bottom image shows Coomassie stain and the reprobe of the same membrane with antibodies to actin. A -fold increase of CUGBP1 (shown below) was calculated as a ratio of (endogenous ϩ His-CUGBP1) signals to CUGBP1 signals observed in wild type animals. D, His-CUGBP1 is hyperphosphorylated in skeletal muscle. His-CUGBP1 was immunoprecipitated from skeletal muscle of CUGBP1 transgenic mice with antibodies to His tag and examined by two-dimensional gel electrophoresis followed by Western blotting with monoclonal antibodies to CUGBP1. The bottom image shows a similar analysis of His-CUGBP1 after treatment with CIP. Spots 1, 2, and 3 represent hyperphosphorylated forms.
total levels of CUGBP1 correlates with the number of transgenic copies (see Table I ). All analyzed animals showed a relatively narrow rate of CUGBP1 overexpression (from 2-to 10-fold), perhaps due to negative effect of CUGBP1 elevation on mouse development (Fig. 2) .
A Severity of Developmental Delay Correlates with Levels of CUGBP1 Elevation-It has been previously shown that transgenic mice overexpressing the human DM1 region with greater than 300 CTG repeats developed myotonia and are growthretarded (10) . Given the accumulation of CUGBP1 in these mice, we performed gross analysis of CUGBP1 transgenic mice from different lines. This analysis showed that mutant mice, in which CUGBP1 is elevated to 2-3-fold (lines 29 and 32), have slight reduction of weight at birth but survive and develop normally. However, transgenic mice, in which CUGBP1 is 4 -6-fold elevated, were growth-retarded and significantly underweight (Fig. 2, A and B) . Analysis of three or four litters from different lines confirmed that weight of newborn CUGBP1 transgenic mice is ϳ5-30% less than their wild type littermates (Table I) and that the reduction of weight depends on the levels of CUGBP1 protein. Animals with 8 -10-fold elevation of CUGBP1 die in utero and are severely underdeveloped (Fig.  2B ). This suggests that the overexpression of CUGBP1 in vivo might have severe impact on mouse development. Given the strongest expression of CUGBP1 transgene in skeletal muscle (Fig. 1C) , we performed cross-sections through hind limb and femur of newborn wild type and mutant (line 36) littermates and found that whereas the size of femur in mutant mice is unchanged, the hind limb muscles look significantly reduced (Fig. 2C) . Therefore, we further focused our studies on the histological analysis of skeletal muscle of CUGBP1 transgenic mice and on molecular pathways by which overexpression of CUGBP1 causes the disorder in skeletal muscle.
His-CUGBP1 Precipitated from Skeletal Muscle of CUGBP1 Transgenic Mice Is Able to Regulate Translation of mRNAs-In
vitro studies have demonstrated that CUGBP1 is a key regulator of translation of p21 and C/EBP␤ mRNAs (12, 21, 22) . To examine whether CUGBP1 displays this activity in vivo, in tissues of transgenic mice, we first determined the RNA binding activity of His-CUGBP1 isolated from these tissues and its ability to regulate translation of mRNA targets. UV cross-link assay of skeletal muscle samples with CUG 123 probe shows that His-CUGBP1, isolated from skeletal muscle cells, is able to interact with the RNA containing CUG repeats (Fig. 2D) . To confirm that His-CUGBP1 binds to RNA, we immunoprecipitated CUGBP1 with antibodies to His tag and examined in a Total skeletal muscle protein extracts were incubated with the CUG 123 probe and analyzed by UV cross-link assay. After UV cross-link, the membrane was stained with Coomassie (below). Positions of His-CUGBP1 (line 32) and endogenous CUGBP1 are shown. The bottom (His-IP) shows UV cross-link with His immunoprecipitates from WT and CUGBP1 transgenic mice. E, His-CUGBP1 increases translation of p21 and LIP in a cell-free translation system. His-CUGBP1 was precipitated from skeletal muscle with His tag Abs and added into reticulocyte lysate programmed with p21 mRNA (top) or with C/EBP␤ mRNA. After translation, p21 or C/EBP␤ was immunoprecipitated and examined by gel electrophoresis. A diagram shows the structure of C/EBP␤ mRNA and the position of the CUGBP1 binding site.
UV cross-link assay. As can be seen in Fig. 2D (his-IP) , His-CUGBP1 interacts with the CUG 123 probe. To perform a functional test for translational activity of His-CUGBP1, CUGBP1 was immunoprecipitated with antibodies to His tag from skeletal muscle and added into a cell-free translation system programmed with p21 or with C/EBP␤ mRNA. These studies demonstrated that His-CUGBP1 precipitated from skeletal muscle of transgenic animals induces translation of p21 mRNA as well as translation of the dominant negative isoform of C/EBP␤, LIP (Fig. 2E) . Thus, these investigations showed that His-CUGBP1 (expressed in tissues of CUGBP1 transgenic mice) binds to RNA and potentially might regulate translation of mRNAs in vivo.
Histological Analyses of Skeletal Muscle from CUGBP1 Transgenic Mice-Histological and immunohistochemical analyses were performed on vastus and, where indicated, on plantaris muscles from the five mutant lines (five mice for line 20, six mice for line 29, five mice for line 32, seven mice for line 36, five mice for line 49) and on control littermates (21 mice). Since 2-3-fold elevation of CUGBP1 was observed in DM1 patients with mild symptoms that often are not apparent for decades, the analysis of this transgenic line was performed with aged mice (1.5 years old). Mutant mice with greater increase of CUGBP1 (4 -6-fold) died between 6 and 12 months. Therefore, histology analysis on these mice was performed using muscles from 6 -8-month-old mice. Mutant mice with the high increase of CUGBP1 (8-fold, line 36) die after birth. H/E staining in this case was performed on newborn pups using cross-sections through hind limb. H/E staining of transverse sections from vastus muscle of wild type mice shows that in wild type mice, most myofibers are of similar diameter with peripheral nuclei (Fig. 3, A and B) . This analysis showed that only 0.3-1% of myofibers in wild type vastus muscle contain internal nuclei. However, in mutant adult mice myofibers were variable in size with an increase of cells containing internal nuclei up to 9.5-21.1% depending on the increase of CUGBP1 (Fig. 3, A and B) . Some myofibers in mutant mice contain nuclei occupying the central position. The presence of internal nuclei in CUGBP1 mutant mice and size variability suggest that the skeletal muscle in these mice is immature. The distance between myofibers was greater in CUGBP1 mutant mice with greater elevation of CUGBP1. We also observed the increase of slow myofibers in CUGBP1 transgenic mice (Fig. 4C) . Comparison of myofiber number in vastus muscles of CUGBP1 transgenic mice (lines 29 and 49) and wild type mice suggests that the myofiber number is slightly (2.5-6.3%) reduced in CUGBP1 mutant mice, perhaps due to increased variability in myofiber size.
Mutant mice with the high increase of CUGBP1 (8-fold, line 36) die after birth. Since congenital DM1 patients have severe underdevelopment of muscles, we focused on the analysis of muscle sections through limbs of new born wild type and transgenic littermates (Fig. 3C) . Two magnified homologous areas from the sections showed that myofibers of CUGBP1 trans- genic mice are variable in length and are shorter than those from wild type mice (Fig. 3D) . Muscle fibers in this line are characterized by prominent nuclei. Analysis of transverse muscle sections showed that 21-33% cells in mutant mice have large nuclei occupying the central position (Fig. 3E) . Several muscle spindles in mutant mice contain clusters of poorly organized fibers with prominent large nuclei (data not shown).
Overexpression of His-CUGBP1 in Skeletal Muscle Leads to Increased Expression of MEF2A and p21-We next examined the molecular basis for the alterations observed in skeletal muscles of CUGBP1 transgenic mice. The presence of short fibers in mutant mice with 8-fold elevation of CUGBP1 (Fig.  3D) suggests that CUGBP1 may disrupt major regulators of late myogenesis, such as myogenin (25) and/or MEF2 factors, which cooperate with basic helix-loop-helix myogenic factors to activate the differentiation program (26, 27) . In a parallel search for the possible regulators of myogenesis that might be targeted by CUGBP1, a muscle-specific library was screened for the transcripts containing the CUGBP1 binding site (CUG repeats and/or GC-rich regions). We identified a member of MEF2 family transcription factors, MEF2A, containing a GCrich region (GCA 9 ) in the position of nucleotide 1565. The other members of this family also contain extensive GC-rich sequences that might be potential binding sites for CUGBP1. Since CUGBP1 up-regulates p21 and MEF2A in cultured cells (12) (see Fig. 6 ), we examined whether these translational targets of CUGBP1 are affected in transgenic mice. As can be seen in Fig. 4A , both p21 and MEF2A are increased in skeletal muscle of transgenic mice. This result was confirmed by immunostaining of skeletal muscle sections. In vastus muscle from wild type mice, strong MEF2A signals were detected only in 20% of fibers. On the contrary, strong MEF2A staining was observed in the majority of cells in vastus muscle from CUGBP1 transgenic mice (line 49) (Fig. 4A) .
In addition to MEF2A, we detected the induction of myogenin in CUGBP1 transgenic mice (Fig. 4A) . The increase of myogenin levels might be a consequence of the MEF2A increase, since the MEF2 family is able to activate myogenin (28) . MyoD levels were not changed in CUGBP1 transgenic mice. Given the alteration of the levels of MEF2A, myogenin, and p21 in skeletal muscle of CUGBP1 transgenic mice, we examined these proteins in muscle of DM1 patients. Similar to CUGBP1 transgenic mice, MEF2A, myogenin, and p21 are elevated in DM1 skeletal muscle (Fig. 4B) . The alterations of CUGBP1, FIG. 4 . Elevation of CUGBP1 in skeletal muscle leads to the induction of MEF2A, myogenin, and p21 protein levels and to alterations of myofiber type. A, elevation of CUGBP1 in skeletal muscle increases levels of MEF2A, p21, and myogenin. Total proteins from vastus muscles were analyzed by Western blotting with various antibodies as indicated. To verify protein loading, each membrane was reprobed with antibodies against actin and stained with Coomassie Blue. Actin control is shown for myogenin and MEF2A filter. Right image, immunostaining of transverse sections of vastus muscle with antibodies against MEF2A. Sections from wild type and transgenic mice with 4 -6-fold elevation of CUGBP1 (line 49) at 8 months of age were analyzed under identical conditions. B, MEF2A, myogenin, and p21 levels are elevated in skeletal muscle of DM1 patients. Protein extracts were isolated from skeletal muscle of normal control and DM1 patient with large CTG expansion (1,500 repeats) and analyzed by Western blotting. Right, CUGBP1, MEF2A, and p21 levels are changed in skeletal muscle of DM1 patients but not in muscle from patients with late onset myopathy. Total protein extracts from DM1 patients with 857 (1) or 300 (2) CTG repeats and from patients with late-onset myopathy (M) were analyzed with antibodies against CUGBP1, p21, MEF2A, and actin as the loading control. Western analysis with CUGBP1 Abs detects CUGBP1 and a weak upper band corresponding to IgG. C, upper image, immunostaining of transverse muscle sections for plantaris muscle from wild type (WT) and mutant mice (line 46) with antibodies against myoglobin and slow and fast myosin heavy chains. Bottom image, the switch of fiber type in skeletal muscle from CUGBP1 transgenic (TR) mice. Total skeletal muscle proteins isolated from vastus muscle of wild type and mutant mice (lines 20, 29, and 46) were examined by Western blotting with antibodies shown on the left. Each membrane was stripped and reprobed with antibodies to actin (not shown) or stained with Coomassie to verify protein loading.
MEF2A, and p21 levels in DM1 muscle are not due to general dystrophy, because the levels of these proteins were unchanged in muscle from patients with late onset myopathy (Fig. 4B) . Thus, the overexpression of CUGBP1 in DM1 patients and in CUGBP1 transgenic mice affects MEF2A and p21 proteins, which play a significant role in myogenesis.
Elevation of CUGBP1, p21, and MEF2A in Skeletal Muscle Is Associated with Alterations of Myofiber Type-At earlier stages of the disease, DM1 patients have an increased number of slow myofibers, which become preferential fibers at later stages of disease progression. Given that p21 and MEF2A are similarly induced in DM1 and CUGBP1 transgenic mice, we examined whether myofiber type is changed in skeletal muscle from CUGBP1 transgenic mice. IF analysis of transverse muscle sections with antibodies against fast myosin shows that in plantaris muscle of 8-month-old wild type mice, fast and intermediate fibers represent 70 -85%. IF analysis of similar sections from mutant littermates (line 49) showed that the number of these fibers is significantly reduced (50%) (Fig. 4C, Fast) . The number of slow fibers determined by IF with antibodies to fast myosin was 15-30% greater, respectively, in CUGBP1 transgenic mice. The increase of slow fibers in CUGBP1 transgenic mice was confirmed by IF with antibodies against slow myosin (Fig. 4C, Slow) . The myofiber-type switch in CUGBP1 transgenic mice was also confirmed by Western analysis of myoglobin and fast and slow myosin. Fig. 4C shows that, in plantaris muscle from CUGBP1 transgenic mice, the levels of slow myosin are increased, whereas the levels of fast myosin are reduced. It is known that slow fibers contain increased levels of myoglobin, and this is in contrast to fast fibers containing lower levels of myoglobin. We determined myoglobin levels by Western blot analysis and IF assay and found that plantaris muscle from CUGBP1 transgenic mice (line 49) has elevated levels of myoglobin, suggesting that the number of slow fibers is greater in CUGBP1 mutant mice. These data suggest that the elevation of CUGBP1 causes alterations in fiber-type composition in skeletal muscle with an increase of slow fibers and reduction of fast fibers similar to DM1 disease.
CUGBP1 Interacts with GCA Repeats Located within MEF2A mRNA-The elevation of MEF2A in skeletal muscle from CUGBP1 transgenic mice prompted us to examine molecular mechanisms by which CUGBP1 increases MEF2A levels. UV cross-link assay with full-length MEF2A mRNA showed that CUGBP1 binds directly to this mRNA and that the affinity of this interaction is similar to that for RNA probe containing CUG 123 (Fig. 5A) . CUGBP1 binds to CAG repeats within MEF2A mRNA, since the deletion of these repeats abolishes the interaction. To confirm the specificity of the interaction, cold MEF2A mRNA and (CAG) 10 -and AU-rich RNA oligomers were incorporated into the binding reactions. As can be seen in Fig. 5A , MEF2A and CAG 10 compete for the binding, whereas AU-rich oligomer does not.
We next determined which RNA-binding domains (RBDs) of CUGBP1 bind to MEF2A mRNA. UV cross-link analysis indicates that full-length CUGBP1 and RBD3 bind to MEF2A mRNA, whereas truncated forms of CUGBP1 containing RBD1ϩ2 and RBD2 do not interact with MEF2A mRNA (Fig.  5B) . Given the in vitro interaction of CUGBP1 with MEF2A mRNA, we asked whether this interaction takes place in vivo. For this goal, we immunoprecipitated CUGBP1 from differentiated C2C12 myotubes and examined the presence of MEF2A mRNA in CUGBP1 IPs using the reverse transcriptase-PCR procedure. In these experiments, we applied primers that cover the GCA repeat within MEF2A mRNA and produce a 743-kb DNA fragment. As can be seen, MEF2A mRNA is detectable in CUGBP1 IPs, whereas MEF2A mRNA is not observed in control precipitates with agarose only (Fig. 5C) . Thus, these studies revealed that CUGBP1 interacts with MEF2A mRNA in vitro and in vivo.
CUGBP1 Increases Translation of MEF2A in a Cell-free Translation System and in Cultured Cells-We next examined whether the interaction of CUGBP1 with MEF2A mRNA affects expression of MEF2A in a cell-free translation system. As can be seen in Fig. 6A , CUGBP1 increases protein levels of MEF2A in the cell-free translation system programmed with the wild type full-length MEF2A mRNA. Deletion of GCA repeats (CUGBP1 binding site) diminishes binding of CUGBP1 to MEF2A mRNA (Fig. 5A ) and leads to a failure of CUGBP1 to induce the translation of mutant MEF2A mRNA (Fig. 6A) . Thus, we conclude that CUGBP1 increases the translation of FIG. 5 . CUGBP1 binds to MEF2A mRNA. A, CUGBP1 interacts with MEF2A mRNA via GCA repeats. Top, bacterially expressed, purified CUGBP1 was incubated with RNA probes CUG 123 , full-length MEF2A mRNA, and ⌬CAG MEF2A mRNA (shown at the top); linked to the probes by UV; and separated by gel electrophoresis. Cold full-length MEF2A mRNA was added to the binding reaction with 32 P-labeled MEF2A mRNA. Coomassie stain of the same membrane is shown. Bottom, cold (CAG) 8 and AU-rich oligomers (100 ng each) were added to the binding reactions with bacterially expressed CUGBP1 and MEF2A mRNA probe. B, CUGBP1 binds to ME2FA mRNA through RBD3. Top, positions of three RBDs within the CUGBP1 molecule. Full-length bacterially expressed CUGBP1 and truncated CUGBP1 proteins containing different RBDs (shown at the top) were incubated with MEF2A mRNA probe and analyzed by UV cross-link assay. C, CUGBP1 binds to MEF2A mRNA in vivo. CUGBP1 was immunoprecipitated from differentiated C2C12 cells (day 3), and RNA was extracted from IPs and examined by reverse transcriptase-PCR with primers specific for MEF2A mRNA.
MEF2A through the interaction with GCA repeats located within MEF2A mRNA.
We next examined whether CUGBP1 increases MEF2A expression in cultured cells using two approaches: transient transfection assay and a stable clone line containing antisense CUGBP1 mRNA under Lac repressor control (21) . The stable clone line contains the inducible antisense CUGBP1 mRNA under control of the Lac repressor. Examination of MEF2A protein levels after the addition of isopropyl-1-thio-␤-D-galactopyranoside revealed that the inhibition of CUGBP1 causes the reduction in the protein levels of MEF2A (Fig. 6B) . To confirm these observations, His-CUGBP1 was transfected into C2C12 cells, and levels of MEF2A were determined by Western blotting. Fig. 6C shows that the levels of His-CUGBP1 expressed from the transfected plasmid are significantly higher than the levels of endogenous CUGBP1 protein. In cells overexpressing CUGBP1, protein levels of MEF2A are dramatically induced. Densitometric analysis of multiple experiments demonstrated an 8 -10-fold induction of MEF2A by CUGBP1 as a ratio to ␤-actin. Immunostaining of transfected cells also revealed that protein levels of MEF2A are dramatically increased in cells overexpressing GFP-CUGBP1 (Fig. 6C, right) . This effect is specific to GFP-CUGBP1, since GFP alone does not increase MEF2A levels. Thus, studies in the cell-free translation system and in cultured cells show that CUGBP1 increases protein levels of MEF2A.
Although data in a cell-free translation system suggest that CUGBP1 increases translation of MEF2A, the CUGBP1-mediated increase of MEF2A levels in transfected cells could be also due to a stabilization of MEF2A protein. To examine this possibility, we determined the half-life of MEF2A protein in C2C12 cells transfected with CUGBP1 or with empty vector as the control. Experiments with cyclohexamide block of protein synthesis showed that MEF2A is a very stable protein and that CUGBP1 does not affect MEF2A stability (Fig. 6D) (Fig.  6E) . Taken together, these investigations show that CUGBP1 increases translation of MEF2A mRNA in a cell-free translation system and in cultured cells.
CUGBP1 Enhances the MEF2A-dependent Myogenic Conversion-The analysis of MEF2A under conditions of overexpression of CUGBP1 showed that CUGBP1 increases translation of MEF2A. We next tested the hypothesis that CUGBP1 might regulate MEF2A during a differentiation course of C2C12 myoblasts. Northern analysis showed that the levels of two major isoforms of CUGBP1 mRNA (7 and 9 kb) are 3-6-fold elevated at days 3 and 5 of differentiation (Fig. 7A) . Western analysis revealed that protein levels of CUGBP1 are also elevated in cytoplasm (Fig. 7B, left) and in nuclei of differentiating C2C12 cells (data not shown). Analysis of p21 and MEF2A expression in the same cell extracts shows an increase of the protein levels of MEF2A and p21, which correlates with the induction of CUGBP1 (Fig. 7B, left) . We next examined whether CUGBP1 interacts with MEF2A mRNA in differentiated myotubes. CUGBP1 was immunoprecipitated from cytoplasmic extracts, and the presence of MEF2A mRNA in CUGBP1 IPs was determined by reverse transcriptase-PCR with specific primers. Fig.  7B (CUGBP1 IP) shows that CUGBP1 is associated with MEF2A mRNA in differentiated myotubes. Our results in a cell-free translation system and these data suggest that CUGBP1 is required for the induction of MEF2A and p21 in differentiating myoblasts. Therefore, we further examined the role of CUGBP1-mediated translational induction of p21 and MEF2A during differentiation of C2C12 cells using siRNAmediated inhibition of CUGBP1. We found that the inhibition of CUGBP1 by siRNA during differentiation leads to a signifi- cant reduction of MEF2A and p21 (Fig. 7B, right) . Thus, these data demonstrate that CUGBP1 is required for the increase of MEF2A and p21 levels during differentiation.
Given the observation that CUGBP1 increases translation of MEF2A, we examined MEF2A levels in cultured myoblasts from control and from DM1 patients during differentiation. In normal myoblasts, MEF2A levels are elevated during differentiation (Fig. 7C) . However, in DM1 cells, the regulation of MEF2A is altered; the levels of CUGBP1 are higher in proliferating myoblasts and lower in differentiating cells (Fig. 7C) . Consistently with low levels of MEF2A, DM1 differentiating myoblasts have lower levels of myosin (data not shown) and are not properly fused (Fig. 7C) . These data suggested that CUGBP1-mediated induction of MEF2A is required for proper differentiation of myoblasts. To examine role of CUGBP1-mediated induction of MEF2A in myogenesis, we applied a tissue culture model of myogenic conversion of mouse fibroblasts 10T1/2 into myoblasts. It is known that although MyoD alone initiates myogenic conversion, the MEF2 family is required to co-activate the myogenesis (27) . We next examined whether direct regulation of MEF2A by CUGBP1 is required for an enhancement of the myogenic conversion. Mouse fibroblasts were co-transfected with MyoD, CUGBP1, and wild type MEF2A or with the GCA deletion mutant MEF2A. If CUGBP1 was co-transfected with wild type MEF2A construct, the efficiency of myogenic conversion was enhanced by ϳ50%. The deletion of the CUGBP1 binding site from MEF2A mRNA abolishes the CUGBP1-dependent enhancement of myogenesis (Fig. 7D) . Thus, these studies revealed that under biologically relevant concentrations and conditions, CUGBP1 enhances myogenic conversion through the regulation of MEF2A.
DISCUSSION
Proper myogenesis requires an orchestrated cascade of expression of muscle specific genes; certain proteins should be expressed at certain stages of muscle development and at certain levels. Such programmed expression of muscle genes is controlled at different levels, including the regulation of transcription and post-transcriptional control. Protein levels of CUGBP1 and RNA binding activity of CUGBP1 are elevated in DM1 patients by expansion of CUG RNA repeats (12, 13, 19 -21) . In this paper, we examine the role of CUGBP1 elevation in DM1 muscle pathology using transgenic mice. The analysis of CUGBP1 transgenic mice shows that the overexpression of CUGBP1 above biological levels is sufficient to disrupt myogenesis in vivo. We found a strong correlation between levels of CUGBP1 elevation and severity of muscle defects. Muscle in mutant mice with 2-3 fold elevation of CUGBP1 shows mild variability in fiber size and increase of internal nuclei only at 1.5-2.0 years of age. Histological muscle phenotype in these mice is similar to that observed in DM1 patients (adult form of DM1) during earlier changes of disease progression. In skeletal muscle of mice with greater increase of CUGBP1 (4 -6-fold, line 49), a larger number of cells was variable in size with accumulation of internal nuclei. Comparison of two transgenic lines shows that mutant mice in line 49 develop muscle histopathology earlier in life (6 -8 months). Elevation of CUGBP1 up to 8-fold causes immaturity of myofibers: central nuclei, increase of nuclei number, shortening of fibers, and reduction in myofiber density. These mice do not survive. Such a phenotype is partially reminiscent of congenital DM1, since immaturity of fibers and fibers with centrally positioning nuclei were found in congenital DM1. The phenotype in this line is stronger than one in congenital DM1, perhaps because the elevation of CUGBP1 in this line is higher than in congenital patients that we analyzed.
Another important similarity between muscle abnormalities in DM1 and in CUGBP1 mice is a myofiber-type switch: increase of slow fibers and reduction of fast fibers. A similar change in fiber type composition can be seen in experimental mice affected with myotonia (29) , which is a hallmark of DM1. Elevation of MEF2A in CUGBP1 transgenic mice is consistent with recent data from Dr. Olson's laboratory indicating that MEF2 activity is elevated in slow fibers in mouse muscles with myotonia (29) . In these myotonic mice, ϳ80% of fibers are oxidative or slow. The elevation of MEF2 activity in muscle of myotonic mice clearly indicates that hyperexcitability of myotonic muscle is associated with up-regulation of MEF2, resulting in increase of slow fibers. A number of proteins have been shown to play a key role in differentiation and development of skeletal muscle. One of these proteins, p21, in collaboration with p57 is involved in the irreversible growth arrest of skeletal muscle cells (30) . Our data from CUGBP1 transgenic mice demonstrate that, in vivo, elevation of CUGBP1 causes an increase of p21 accompanied by delay of muscle development and dystrophic histopathology in muscle. Since CUGBP1 increases translation of p21 in cultured cells (12) , it is likely that translation of p21 is also induced in skeletal muscle of DM1 patients. On the other hand, alterations in p21 mRNA may also contribute to increased levels of p21 protein. What is a possible mechanism by which increase of p21 might delay myogenesis in DM1 and in CUGBP transgenic mouse muscles? It has been recently shown that p21 may play opposite roles in the regulating cell proliferation: 1) arrest of proliferation by inhibiting Cdk2-cyclin E and 2) promotion of proliferation by stimulating the assembly of active Cdk4-cyclin D1 complexes (31) . Therefore, elevated levels of p21 in DM1 tissues might lead to both inhibition and promotion of proliferation depending on the protein environment at the cell cycle stage when p21 is elevated. Since differentiation requires a tightly regulated cascade of gene expression and precise amounts of the proteins, we suggest that CUGBP1-mediated overexpression of p21 in DM1 tissues inhibits differentiation of skeletal muscle.
Myogenesis is also regulated by myogenic basic helix-loophelix transcription factors (MyoD, Myf-5, myogenin, and MFR4) and their co-activators, MEF2 factors. An increase of myogenic transcription factors and their co-activators is required for the activation of myogenesis. In CUGBP1 transgenic mice, however, an increase of MEF2A and myogenin is associated with a delay of myogenesis. We hypothesize that such a paradox occurs because of misregulation of myogenic transcription factors. For proper myogenesis, these factors should be regulated in a very precise manner. However, forced increase of CUGBP1 in mice might result in unscheduled activation of myogenic factors at the wrong time of development, delaying myogenesis. It is interesting to note that both deletion and overexpression of myogenin in mice leads to neo-or postnatal death (32, 33) , showing that normal development requires a tight regulation of myogenin.
A similar phenomenon has also been described for MEF2A. Since MEF2A activates transcription of many muscle proteins, precise timing and levels of MEF2A expression are required to provide distinct levels of specific proteins at the correct stage of muscle development. Such regulation has been earlier described for MEF2A. It has been found that the 3Ј-untranslated region of MEF2A mRNA is responsible for regulating its own mRNA translation during differentiation (34) . This regulation leads to low levels of MEF2A in proliferating myoblasts via inhibition of MEF2A translation and high levels of MEF2A in differentiating myoblasts due to lack of repression of MEF2A translation. Another publication also found that proper regulation of MEF2 levels is required for differentiation (35) . In this paper, the authors show that too little or too much MEF2 activity leads to the same result: disruption of differentiation (35) . Taking into account these observations, we suggest that too much CUGBP1 activity in CUGBP1 transgenic mice delays myogenesis.
CUGBP1 is located in nuclei and cytoplasm and is able to regulate both RNA splicing and mRNA translation. In this paper, we focused our studies on the translational function of CUGBP1. Based on our observations, we suggest a hypothetical pathway by which the cytoplasmic portion of CUGBP1 contributes to DM1 pathology in skeletal muscle (Fig. 8) . We hypothesize that in normal differentiating cells, CUGBP1 causes an increase of MEF2A and p21 at the correct time. In DM1 patients, basal overexpression of CUGBP1 caused by CUG repeats leads to overall overexpression of p21 and MEF2A that results in inhibition of myogenesis.
